Global contract research organisation (CRO) Premier Research has appointed Martin Nicklasson, the former CEO of AstraZeneca Sweden, to its Board of Directors.
Nicklasson is a native of Sweden with international biopharmaceutical experience at executive and board level. In addition to his role at AstraZeneca, he served as CEO of Biovitrum before retiring to found Nicklasson Life Science. He currently chairs the Board of Directors of Basilea Pharmaceuticals, Orexo AB, and Farma Holdings AS, and is a non-executive director of Biocrine AB, Pozen Inc, and Oasmia AB.
Premier Research’s R&D work focuses on analgaesia, the central nervous system, rare diseases, medical devices and paediatric research.
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Plus promotions and hires in outsourced pharma.